BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 28204918)

  • 1. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
    Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
    World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
    Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
    Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
    O'Farrell S; Sandström K; Garmo H; Stattin P; Holmberg L; Adolfsson J; Van Hemelrijck M
    BJU Int; 2016 Sep; 118(3):391-8. PubMed ID: 26497726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
    Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
    Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
    Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
    Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between ischaemic bowel syndromes and androgen deprivation therapy in patients with prostate cancer: a retrospective cohort study.
    Chiang IN; Huang CY; Pu YS; Chang CH; Muo CH; Chung CJ; Wang RY; Young TH
    BMJ Open; 2017 Feb; 7(2):e012950. PubMed ID: 28246133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
    Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia.
    Hicks BM; Yin H; Bladou F; Ernst P; Azoulay L
    Thorax; 2017 Jul; 72(7):596-597. PubMed ID: 27986803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy.
    Mikkelsen MK; Thomsen FB; Berg KD; Jarden M; Larsen SB; Hansen RB; Brasso K
    Scand J Urol; 2017 Dec; 51(6):464-469. PubMed ID: 28831860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
    Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
    JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
    Haque R; UlcickasYood M; Xu X; Cassidy-Bushrow AE; Tsai HT; Keating NL; Van Den Eeden SK; Potosky AL
    Br J Cancer; 2017 Oct; 117(8):1233-1240. PubMed ID: 29017178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
    Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
    BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.
    Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S
    Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
    Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
    JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
    Nead KT; Gaskin G; Chester C; Swisher-McClure S; Dudley JT; Leeper NJ; Shah NH
    J Clin Oncol; 2016 Feb; 34(6):566-71. PubMed ID: 26644522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.